Investment Analysts’ Weekly Ratings Changes for Allogene Therapeutics (ALLO)

Several analysts have recently updated their ratings and price targets for Allogene Therapeutics (NASDAQ: ALLO):

• 1/9/2026 – Allogene Therapeutics was upgraded by analysts at Citigroup Inc. from a “market perform” rating to an “outperform” rating.
• 1/9/2026 – Allogene Therapeutics was upgraded by analysts at Citizens Jmp from a “market perform” rating to an “outperform” rating. They now have a $5.00 price target on the stock.
• 1/7/2026 – Allogene Therapeutics is now covered by analysts at UBS Group AG. They set a “buy” rating and a $8.00 price target on the stock.
• 1/7/2026 – Allogene Therapeutics is now covered by analysts at UBS Group AG. They set a “buy” rating and a $8.00 price target on the stock.
• 11/28/2025 – Allogene Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.

Insider Buying and Selling

In other Allogene Therapeutics news, CFO Geoffrey M. Parker sold 36,744 shares of the business’s stock in a transaction that occurred on Tuesday, October 21st. The shares were sold at an average price of $1.26, for a total transaction of $46,297.44. Following the sale, the chief financial officer owned 1,276,796 shares of the company’s stock, valued at approximately $1,608,762.96. The trade was a 2.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 13.20% of the stock is owned by insiders.

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.